We are live on ! Find out more
SCV

Sands Capital Ventures Portfolio holdings

AUM $614M
1-Year Est. Return 19.92%
This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$344M
AUM Growth
-$20.1M
Cap. Flow
-$41M
Cap. Flow %
-11.91%
Top 10 Hldgs %
93.26%
Holding
19
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$23.1M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 44.44%
2 Technology 25.72%
3 Financials 11.68%
4 Consumer Discretionary 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DICE
1
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$63.9M 18.56%
3,148,970
– –
PATH icon
2
UiPath
PATH
$8.3B
$48.1M 13.97%
3,811,779
– –
NU icon
3
Nu Holdings
NU
$73.6B
$40.2M 11.68%
9,136,835
– –
SNOW icon
4
Snowflake
SNOW
$114B
$36.5M 10.6%
214,621
– –
ABOS icon
5
Acumen Pharmaceuticals
ABOS
$193M
$34.3M 9.96%
3,417,075
– –
DASH icon
6
DoorDash
DASH
$94B
$29.7M 8.64%
601,454
– –
TXG icon
7
10x Genomics
TXG
$7.31B
$13.7M 3.99%
481,770
– –
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$13.2M 3.85%
58,895
-114,000
-66% -$23.1M
OLK
9
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$8.56M 2.49%
705,514
– –
MASS icon
10
908 Devices
MASS
$414M
$5.37M 1.56%
326,427
– –
TARS icon
11
Tarsus Pharmaceuticals
TARS
$3.04B
$4.45M 1.29%
260,000
– –
RGEN icon
12
Repligen
RGEN
$9.42B
$4.22M 1.23%
22,544
– –
IOT icon
13
Samsara
IOT
$23.2B
$3.94M 1.14%
326,000
– –
CADL icon
14
Candel Therapeutics
CADL
$897M
$2.55M 0.74%
811,737
– –
TSHA icon
15
Taysha Gene Therapies
TSHA
$1.94B
$1.4M 0.41%
724,873
– –
SPRB
16
Spruce Biosciences
SPRB
$151M
$1.08M 0.31%
10,493
– –
ABSI icon
17
Absci
ABSI
$1.58B
$181K 0.05%
57,804
– –
CINC
18
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-950,000
Closed -$17.9M

Similar funds

T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $613M AUM 14.25% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $613M AUM 30.37% 1-Year Est. Return
MKA
M. Kulyk & Associates Decatur, Georgia $613M AUM 22.75% 1-Year Est. Return
CSIA
Conrad Siegel Investment Advisors Harrisburg, Pennsylvania $615M AUM 21.19% 1-Year Est. Return
ATFA
All Terrain Financial Advisors Coon Rapids, Minnesota $615M AUM 30.42% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $615M AUM 25.07% 1-Year Est. Return
FWM
Fonville Wealth Management Richmond, Virginia $612M AUM 18.82% 1-Year Est. Return
FSA
Financial Security Advisor Virginia Beach, Virginia $615M AUM 26.08% 1-Year Est. Return

Sands Capital Ventures's Q3 2022 Portfolio in Review

As of Q3 2022, Sands Capital Ventures held 19 positions worth $344M, down 5.5% from $364M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Sands Capital Ventures withdrew a net $41M in Q3 2022, closing 1 position and reducing 1 holding. Its most notable exit was CinCor Pharma, Inc. Common Stock, an estimated $17.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 43% a quarter earlier, followed by Technology and Financials.

  • Sands Capital Ventures's biggest Q3 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $23.1M.
  • Sands Capital Ventures fully exited CinCor Pharma, Inc. Common Stock in Q3 2022, selling an estimated $17.9M.
  • Sands Capital Ventures's ten largest holdings make up 93% of its $344M portfolio in Q3 2022.
  • Sands Capital Ventures opened 0 new positions and closed 1 in Q3 2022.
  • Sands Capital Ventures's portfolio value fell 5.5% quarter-over-quarter to $344M.

Based on Sands Capital Ventures's 13F filing for Q3 2022, filed 9 Nov 2022.